Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label Study of the Safety and Tolerability of Repeated Administration of a 200-mcg Dose of IPP-201101 Plus Standard of Care in Patients With Systemic Lupus Erythematosus

Trial Profile

An Open-label Study of the Safety and Tolerability of Repeated Administration of a 200-mcg Dose of IPP-201101 Plus Standard of Care in Patients With Systemic Lupus Erythematosus

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 05 Dec 2018

At a glance

  • Drugs Forigerimod (Primary)
  • Indications Systemic lupus erythematosus
  • Focus Adverse reactions; Registrational
  • Acronyms IP-006
  • Sponsors ImmuPharma
  • Most Recent Events

    • 28 Nov 2018 Planned End Date changed from 1 Oct 2018 to 1 Mar 2019.
    • 28 Nov 2018 Planned primary completion date changed from 1 Oct 2018 to 1 Feb 2019.
    • 28 Nov 2018 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top